These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 11557704)

  • 1. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial.
    Naumann M; Lowe NJ
    BMJ; 2001 Sep; 323(7313):596-9. PubMed ID: 11557704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study.
    Naumann M; Lowe NJ; Kumar CR; Hamm H;
    Arch Dermatol; 2003 Jun; 139(6):731-6. PubMed ID: 12810503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial.
    Naumann MK; Hamm H; Lowe NJ;
    Br J Dermatol; 2002 Dec; 147(6):1218-26. PubMed ID: 12452874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin A for axillary hyperhidrosis (excessive sweating).
    Heckmann M; Ceballos-Baumann AO; Plewig G;
    N Engl J Med; 2001 Feb; 344(7):488-93. PubMed ID: 11172190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis.
    Baumann L; Slezinger A; Halem M; Vujevich J; Martin LK; Black L; Bryde J
    Int J Dermatol; 2005 May; 44(5):418-24. PubMed ID: 15869543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis.
    Simonetta Moreau M; Cauhepe C; Magues JP; Senard JM
    Br J Dermatol; 2003 Nov; 149(5):1041-5. PubMed ID: 14632812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study between intradermal botulinum toxin A and fractional microneedle radiofrequency (FMR) for the treatment of primary axillary hyperhidrosis.
    Rummaneethorn P; Chalermchai T
    Lasers Med Sci; 2020 Jul; 35(5):1179-1184. PubMed ID: 31939036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study.
    Vadoud-Seyedi J; Simonart T
    Br J Dermatol; 2007 May; 156(5):986-9. PubMed ID: 17286630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of axillary hyperhidrosis with botulinum-A toxin.
    Salmanpoor R; Rahmanian MJ
    Int J Dermatol; 2002 Jul; 41(7):428-30. PubMed ID: 12121560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin type A in the treatment of bilateral primary axillary hyperhidrosis: efficacy and duration with repeated treatments.
    Lowe PL; Cerdan-Sanz S; Lowe NJ
    Dermatol Surg; 2003 May; 29(5):545-8. PubMed ID: 12752526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Same-patient prospective comparison of Botox versus Dysport for the treatment of primary axillary hyperhidrosis and review of literature.
    Vergilis-Kalner IJ
    J Drugs Dermatol; 2011 Sep; 10(9):1013-5. PubMed ID: 22052270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin in the treatment of axillary hyperhidrosis.
    Galadari I; Alkaabi J
    Skinmed; 2003; 2(4):209-11. PubMed ID: 14673273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin type A vs type B for axillary hyperhidrosis in a case series of patients observed for 6 months.
    Frasson E; Brigo F; Acler M; Didonè G; Vicentini S; Bertolasi L
    Arch Dermatol; 2011 Jan; 147(1):122-3. PubMed ID: 21242408
    [No Abstract]   [Full Text] [Related]  

  • 14. Dilution of botulinum toxin A in lidocaine vs. in normal saline for the treatment of primary axillary hyperhidrosis: a double-blind, randomized, comparative preliminary study.
    Güleç AT
    J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):314-8. PubMed ID: 21492253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower relapse rate of botulinum toxin A therapy for axillary hyperhidrosis by dose increase.
    Karamfilov T; Konrad H; Karte K; Wollina U
    Arch Dermatol; 2000 Apr; 136(4):487-90. PubMed ID: 10768647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term quantitative benefits of botulinum toxin type A in the treatment of axillary hyperhidrosis.
    Odderson IR
    Dermatol Surg; 2002 Jun; 28(6):480-3. PubMed ID: 12081675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose botulinum toxin type A therapy for axillary hyperhidrosis markedly prolongs the relapse-free interval.
    Wollina U; Karamfilov T; Konrad H
    J Am Acad Dermatol; 2002 Apr; 46(4):536-40. PubMed ID: 11907503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The place of botulinum toxin type A in the treatment of focal hyperhidrosis.
    Lowe N; Campanati A; Bodokh I; Cliff S; Jaen P; Kreyden O; Naumann M; Offidani A; Vadoud J; Hamm H
    Br J Dermatol; 2004 Dec; 151(6):1115-22. PubMed ID: 15606505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis.
    Schnider P; Binder M; Kittler H; Birner P; Starkel D; Wolff K; Auff E
    Br J Dermatol; 1999 Apr; 140(4):677-80. PubMed ID: 10233320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffusion and short-term efficacy of botulinum toxin A after the addition of hyaluronidase and its possible application for the treatment of axillary hyperhidrosis.
    Goodman G
    Dermatol Surg; 2003 May; 29(5):533-8; discussion 538. PubMed ID: 12752524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.